Zhejiang Hisun Pharmaceutical (SHA:600267) and subsidiary Hanhui Pharmaceutical won pre-bids for five products under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.
Three of the drugs are antibiotic injections, including imipenem and cilastatin sodium, vancomycin hydrochloride, and teicoplanin.
Two other products, tacrolimus for injection and epirubicin hydrochloride, are chemotherapy drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments